Clinical trial
Long-term Treatment Study of MRA for Systemic Juvenile Idiopathic Arthritis…
NCT00144612 · Chugai Pharmaceutical, Industry · Completed
Key facts
| NCT number | NCT00144612 |
|---|---|
| Title | Long-term Treatment Study of MRA for Systemic Juvenile Idiopathic Arthritis (sJIA) |
| Official title | An Open-label, Extension, Phase III Study to Evaluate the Long-term Safety and Efficacy of MRA in Patients With sJIA Who Participated in Studies MRA011JP or MRA316JP |
| Lead sponsor | Chugai Pharmaceutical, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Systemic Juvenile Idiopathic Arthritis |
| Intervention type | Drug |
| Interventions | MRA(Tocilizumab) |
| Enrollment | 60 |
| Start date | Jul 1, 2004 |
| Primary completion | Jun 1, 2005 |
| Completion | Jun 1, 2009 |
| First posted | Sep 5, 2005 |
| Last update posted | Dec 23, 2009 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: